Article citationsMore>>

Bai, S., Tian, T., Pacheco, J.M., Tachihara, M., Hu, P. and Zhang, J. (2021) Immune-related Adverse Event Profile of Combination Treatment of PD-(L)1 Checkpoint Inhibitors and Bevacizumab in Non-Small Cell Lung Cancer Patients: Data from the FDA Adverse Event Reporting System. Translational Lung Cancer Research, 10, 2614-2624.
https://doi.org/10.21037/tlcr-21-464

has been cited by the following article:

• TITLE: Research Progress on the Role of the PD-1/PD-L1 Pathway in Immune Thrombocytopenia

  AUTHORS: Ling Ge

  KEYWORDS: PD-1 Inhibitor, PD-L1 Inhibitor, Immune Thrombocytopenia, Immune-Related Adverse Events, Immune Tolerance

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.16 No.2, May 19, 2026

  ABSTRACT: The widespread use of immune checkpoint inhibitors (ICIs), particularly Programmed cell death protein 1/programmed death ligand 1(PD-1/PD-L1) inhibitors, has significantly improved the survival prognosis of patients with various malignancies but has also brought about unique immune-related adverse events (irAEs). Among these, ICI-related immune thrombocytopenia (ITP), a rare but potentially life-threatening hematologic adverse event, is gaining increasing clinical attention. This article systematically reviews the pathogenic mechanisms of ITP associated with PD-1/PD-L1 inhibitors and explores the potential role of the PD-1/PD-L1 pathway in the pathogenesis of primary ITP. A deep understanding of the bidirectional relationship between the PD-1/PD-L1 pathway and ITP is of great significance for optimizing the safety management of tumor immunotherapy and exploring novel therapeutic strategies for ITP.